Microbiota-Driven Immune Regulation in Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) arises from a complex interplay between host genetics, immune responses and the intestinal microbiota. The gut microbial community influences mucosal immunity through microbial‐derived metabolites, pattern recognition receptor signalling and modulation of epithelial barrier integrity. Key receptors such as NOD2 and inflammasomes sense bacterial components and orchestrate downstream cytokine networks that maintain intestinal homeostasis. Disruption of this equilibrium—termed dysbiosis—can trigger exaggerated inflammatory cascades, loss of regulatory T‐cell function and epithelial injury. Recent advances reveal that specific bacterial enzymes generate ligands for innate sensors, while host genetic variants shape microbial composition, creating reciprocal feedback loops. Understanding these mechanisms has global significance, as it suggests targeted microbial or immunomodulatory therapies to restore eubiosis, reinforce barrier function and dampen pathogenic inflammation in Crohn’s disease and ulcerative colitis.

Research from Nature Portfolio

Researchers have identified a secreted peptidoglycan hydrolase from probiotic Lactobacillus strains that generates muramyl dipeptide, a NOD2 ligand. In colitis models, this enzyme enhances NOD2 signalling, reduces inflammatory cytokines and protects against colitis‐associated colorectal cancer. In parallel, studies of the NLRP1 inflammasome reveal that its activation limits butyrate‐producing Clostridiales, reducing protective short‐chain fatty acids and exacerbating experimental colitis. Deficiency of NLRP1 or supplementation with butyrate restores beneficial commensals and alleviates inflammation, with supportive data from human ulcerative colitis biopsies showing an inverse relationship between NLRP1–IL-18–IFNγ expression and Clostridiales abundance. Foundational work in NOD2-deficient mice demonstrates that loss of NOD2 alters gut community structure, enriches regulatory bacterial taxa and increases lamina propria regulatory T-cell subsets, resulting in milder colitis after chemical injury. Cohousing experiments confirm that microbiota transfer can modulate disease severity, highlighting the therapeutic promise of manipulating microbial assemblies.

Microbiota-Driven Immune Regulation in Inflammatory Bowel Disease publication trend

The graph below shows the total number of articles in microbiota-driven immune regulation in inflammatory bowel disease across all publications each year (not limited to Nature Index journals).

Technical terms

Microbiota: The community of microorganisms, including bacteria, fungi and viruses, inhabiting the gastrointestinal tract.

Dysbiosis: An imbalance in microbial composition or function that disrupts host–microbe symbiosis and can promote disease.

NOD2: A cytosolic pattern recognition receptor that senses muramyl dipeptide from bacterial peptidoglycan and regulates mucosal immune responses.

Inflammasome: A multiprotein complex in innate immune cells that activates inflammatory cytokines, such as IL-1β and IL-18, in response to microbial or danger signals.

Butyrate: A short-chain fatty acid produced by certain gut bacteria that serves as an energy source for colonocytes and exerts anti-inflammatory effects.

References

1. A probiotic bi-functional peptidoglycan hydrolase sheds NOD2 ligands to regulate gut homeostasis in female mice. Nature Communications (2023).
2. NLRP1 restricts butyrate producing commensals to exacerbate inflammatory bowel disease. Nature Communications (2018).
3. Nod2 Deficiency in mice is Associated with Microbiota Variation Favouring the Expansion of mucosal CD4+ LAP+ Regulatory Cells. Scientific Reports (2018).
4. NOD2-mediated dual negative regulation of inflammatory responses triggered by TLRs in the gastrointestinal tract. Frontiers in Immunology (2024).
5. The crosstalk between microbial sensors ELMO1 and NOD2 shape intestinal immune responses. Virulence (2023).
6. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. Journal of Clinical Investigation (2013).